Effect of pentoxifylline on endothelial dysfunction, oxidative stress and inflammatory markers in STEMI patients

Aim: ST-elevation myocardial infarction (STEMI) patients suffer higher mortality and adverse outcomes linked to endothelial dysfunction (ED). Methods: 43 patients were randomized to pentoxifylline (PTX) 400 mg thrice daily (n = 22) or placebo (n = 21). Soluble vascular cell adhesion molecule-1, malo...

Full description

Saved in:
Bibliographic Details
Main Authors: Asmaa Saeed, Mohamed Moustafa Farouk, Nagwa Ali Sabri, Mohamed Ayman Saleh, Marwa Adel Ahmed
Format: Article
Language:English
Published: Taylor & Francis Group 2024-12-01
Series:Future Science OA
Subjects:
Online Access:https://www.tandfonline.com/doi/10.2144/fsoa-2023-0266
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1850099358767251456
author Asmaa Saeed
Mohamed Moustafa Farouk
Nagwa Ali Sabri
Mohamed Ayman Saleh
Marwa Adel Ahmed
author_facet Asmaa Saeed
Mohamed Moustafa Farouk
Nagwa Ali Sabri
Mohamed Ayman Saleh
Marwa Adel Ahmed
author_sort Asmaa Saeed
collection DOAJ
description Aim: ST-elevation myocardial infarction (STEMI) patients suffer higher mortality and adverse outcomes linked to endothelial dysfunction (ED). Methods: 43 patients were randomized to pentoxifylline (PTX) 400 mg thrice daily (n = 22) or placebo (n = 21). Soluble vascular cell adhesion molecule-1, malondialdehyde, interleukin-1 (IL-1), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-α (TNF-α) were assessed at baseline and 2 months. Results: After 2 months, no significant difference was observed in markers' levels between the 2 groups. However, a within-group comparison revealed a statistically significant change in hs-CRP in the PTX group (10.057 (9.779–10.331) versus 9.721 (6.102–10.191)), p = 0.032. Conclusion: PTX for 2 months in STEMI patients was safe and well-tolerated but had no significant detectable effect on ED, oxidative stress or inflammatory markers.Clinical Trial Registration: NCT04367935 (ClinicalTrials.gov)
format Article
id doaj-art-1da8d14e697244ef9c3dfe81c7e9c5b6
institution DOAJ
issn 2056-5623
language English
publishDate 2024-12-01
publisher Taylor & Francis Group
record_format Article
series Future Science OA
spelling doaj-art-1da8d14e697244ef9c3dfe81c7e9c5b62025-08-20T02:40:30ZengTaylor & Francis GroupFuture Science OA2056-56232024-12-0110110.2144/fsoa-2023-0266Effect of pentoxifylline on endothelial dysfunction, oxidative stress and inflammatory markers in STEMI patientsAsmaa Saeed0Mohamed Moustafa Farouk1Nagwa Ali Sabri2Mohamed Ayman Saleh3Marwa Adel Ahmed4Department of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, EgyptDepartment of Cardiology, Faculty of Medicine, Ain Shams University, Cairo, 11591 EgyptDepartment of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, EgyptDepartment of Cardiology, Faculty of Medicine, Ain Shams University, Cairo, 11591 EgyptDepartment of Clinical Pharmacy, Faculty of Pharmacy, Ain Shams University, Cairo, 11566, EgyptAim: ST-elevation myocardial infarction (STEMI) patients suffer higher mortality and adverse outcomes linked to endothelial dysfunction (ED). Methods: 43 patients were randomized to pentoxifylline (PTX) 400 mg thrice daily (n = 22) or placebo (n = 21). Soluble vascular cell adhesion molecule-1, malondialdehyde, interleukin-1 (IL-1), interleukin-6 (IL-6), high-sensitivity C-reactive protein (hs-CRP) and tumor necrosis factor-α (TNF-α) were assessed at baseline and 2 months. Results: After 2 months, no significant difference was observed in markers' levels between the 2 groups. However, a within-group comparison revealed a statistically significant change in hs-CRP in the PTX group (10.057 (9.779–10.331) versus 9.721 (6.102–10.191)), p = 0.032. Conclusion: PTX for 2 months in STEMI patients was safe and well-tolerated but had no significant detectable effect on ED, oxidative stress or inflammatory markers.Clinical Trial Registration: NCT04367935 (ClinicalTrials.gov)https://www.tandfonline.com/doi/10.2144/fsoa-2023-0266acute coronary syndromeendothelial dysfunctioninflammationmalondialdehydeoxidative stresspentoxifylline
spellingShingle Asmaa Saeed
Mohamed Moustafa Farouk
Nagwa Ali Sabri
Mohamed Ayman Saleh
Marwa Adel Ahmed
Effect of pentoxifylline on endothelial dysfunction, oxidative stress and inflammatory markers in STEMI patients
Future Science OA
acute coronary syndrome
endothelial dysfunction
inflammation
malondialdehyde
oxidative stress
pentoxifylline
title Effect of pentoxifylline on endothelial dysfunction, oxidative stress and inflammatory markers in STEMI patients
title_full Effect of pentoxifylline on endothelial dysfunction, oxidative stress and inflammatory markers in STEMI patients
title_fullStr Effect of pentoxifylline on endothelial dysfunction, oxidative stress and inflammatory markers in STEMI patients
title_full_unstemmed Effect of pentoxifylline on endothelial dysfunction, oxidative stress and inflammatory markers in STEMI patients
title_short Effect of pentoxifylline on endothelial dysfunction, oxidative stress and inflammatory markers in STEMI patients
title_sort effect of pentoxifylline on endothelial dysfunction oxidative stress and inflammatory markers in stemi patients
topic acute coronary syndrome
endothelial dysfunction
inflammation
malondialdehyde
oxidative stress
pentoxifylline
url https://www.tandfonline.com/doi/10.2144/fsoa-2023-0266
work_keys_str_mv AT asmaasaeed effectofpentoxifyllineonendothelialdysfunctionoxidativestressandinflammatorymarkersinstemipatients
AT mohamedmoustafafarouk effectofpentoxifyllineonendothelialdysfunctionoxidativestressandinflammatorymarkersinstemipatients
AT nagwaalisabri effectofpentoxifyllineonendothelialdysfunctionoxidativestressandinflammatorymarkersinstemipatients
AT mohamedaymansaleh effectofpentoxifyllineonendothelialdysfunctionoxidativestressandinflammatorymarkersinstemipatients
AT marwaadelahmed effectofpentoxifyllineonendothelialdysfunctionoxidativestressandinflammatorymarkersinstemipatients